Sign In
Buy EFTR
$0.0006
+0 (+0%)
At Close: Jun 03, 2026
Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
02:08am, Tuesday, 06'th Jan 2026
Volatility and Risk eFFECTOR Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.44, suggesting that its sto
eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast
02:30am, Saturday, 22'nd Nov 2025
Profitability This table compares eFFECTOR Therapeutics and NexImmune's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A
Critical Analysis: eFFECTOR Therapeutics (NASDAQ:EFTR) vs. Antibe Therapeutics (OTCMKTS:ATBPD)
01:18am, Wednesday, 22'nd Oct 2025
Valuation and Earnings This table compares eFFECTOR Therapeutics and Antibe Therapeutics"s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
07:00am, Wednesday, 04'th Dec 2024
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that de
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
09:00am, Monday, 15'th Jul 2024
As the stock market hits new highs in July, investors are riding a wave of optimism, closely tracking climbing indexes. Yet, beneath this bullish surface, some publicly traded companies are becoming b
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (S
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
10:56pm, Thursday, 09'th May 2024
eFFECTOR Therapeutics (NASDAQ: EFTR ) just reported results for the first quarter of 2024. eFFECTOR Therapeutics reported earnings per share of -$2.16.
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:01pm, Thursday, 09'th May 2024
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
08:00am, Tuesday, 09'th Apr 2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
02:01pm, Friday, 05'th Apr 2024
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
04:01pm, Monday, 25'th Mar 2024
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:30am, Monday, 05'th Feb 2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
10:56am, Tuesday, 30'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is que
